Completed PHASE1 INTERVENTIONAL 1-arm NCT03302728

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (EpiBrentlen)

A Phase 1b Study of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-cell Lymphoma, CD30-positive Peripheral T-cell Lymphoma, or CD30-positive Hodgkin Lymphoma

Sponsor: Peter MacCallum Cancer Centre, Australia

Conditions Hodgkin Lymphoma Lymphoma, T-Cell, Cutaneous Lymphoma, T-Cell, Peripheral

Interventions Brentuximab Vedotin 1.8 mg/Kg Lenalidomide 15mg

Updated 7 times since 2017 Last updated: May 17, 2022 Started: Aug 30, 2018 Primary completion: Aug 2, 2021 Completion: Aug 2, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hodgkin Lymphoma and Lymphoma, T-Cell, Cutaneous, this trial is completed. The trial is conducted by Peter MacCallum Cancer Centre, Australia and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2021 — Jun 2022 [monthly]

Recruiting PHASE1
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jun 2018 — Oct 2020 [monthly]

Not Yet Recruiting PHASE1
Oct 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peter MacCallum Cancer Centre, Australia

Data source: Peter MacCallum Cancer Centre, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia